Enliven Treateutics(ELVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ELVN Enliven Treateutics

Trading 03-26 11:10:49 EDT

21.15

-0.17

-0.80%

High21.62	Low21.13	Vol9.34K
Open21.25	D1 Closing21.32	Amplitude2.29%
Mkt Cap1.04B	Tradable Cap569.52M	Total Shares49.00M
T/O198.47K	T/O Rate0.03%	Tradable Shares26.93M
P/B3.35	ROE-32.04%	EPS-1.89
52wk High30.03	52wk Low15.96	P/E-11.18
Dividend0.00	Div.Yield0.00	ROA-21.87%

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ELVN","market":"US","secType":"STK","nameCN":"Enliven Treateutics","latestPrice":21.15,"timestamp":1743001824316,"preClose":21.32,"halted":0,"volume":9335,"delay":0,"floatShares":26927485,"shares":49004425,"eps":-1.891209,"marketStatus":"Trading","change":-0.17,"latestTime":"03-26 11:10:49 EDT","open":21.25,"high":21.6192,"low":21.13,"amount":198473.479365,"amplitude":0.022946,"askPrice":21.27,"askSize":340,"bidPrice":21.05,"bidSize":8,"shortable":3,"etf":0,"ttmEps":-1.891209,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743019200000},"marketStatusCode":2,"adr":0,"listingDate":1583985600000,"exchange":"NASDAQ","adjPreClose":21.32,"preHourTrading":{"tag":"盘前","latestPrice":22,"preClose":21.32,"latestTime":"08:00 EDT","volume":202,"amount":4443.340066,"timestamp":1742990400220},"postHourTrading":{"tag":"盘后","latestPrice":21.32,"preClose":21.32,"latestTime":"16:05 EDT","volume":3595,"amount":76645.4,"timestamp":1742933109259},"volumeRatio":0.139389,"impliedVol":0.6253,"impliedVolPercentile":0.392},"requestUrl":"/m/hq/s/ELVN/wiki","defaultTab":"wiki","newsList":[{"id":"2521887332","title":"Enliven Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2521887332","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521887332?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 20:02","pubTimestamp":1742558520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ELVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 21, 2025 08:02 ET (12:02 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ELVN"],"gpt_icon":0},{"id":"2521405830","title":"Enliven Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $39 From $37","url":"https://stock-news.laohu8.com/highlight/detail?id=2521405830","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521405830?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 18:09","pubTimestamp":1742551758,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nAZN3LCIPM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2519860619","title":"Enliven Therapeutics Q4 Operating Expenses USD 26.896 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2519860619","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519860619?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 05:52","pubTimestamp":1741902739,"startTime":"0","endTime":"0","summary":"March 13 (Reuters) - Enliven Therapeutics Inc ::*ENLIVEN THERAPEUTICS Q4 OPERATING EXPENSES USD 26.896 MILLION*ENLIVEN THERAPEUTICS Q4 NET INCOME USD -23.18 MILLION*ENLIVEN THERAPEUTICS Q4 INCOME FROM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nRSD3nspJt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN"],"gpt_icon":0},{"id":"2519861834","title":"Enliven Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2519861834","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519861834?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 04:21","pubTimestamp":1741897318,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryEnliven Therapeutics Inc ELVN.OQ reported a quarterly adjusted loss of 46 cents per share for the quarter e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL8N3PW21A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN"],"gpt_icon":0},{"id":"2508834634","title":"Strong Buy Recommendation for Enliven Therapeutics Due to ELVN-001’s High Selectivity and Promising Clinical Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2508834634","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508834634?lang=en_us&edition=full_marsco","pubTime":"2025-02-04 13:35","pubTimestamp":1738647322,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics (ELVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Salim Syed ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strong-buy-recommendation-for-enliven-therapeutics-due-to-elvn-001s-high-selectivity-and-promising-clinical-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strong-buy-recommendation-for-enliven-therapeutics-due-to-elvn-001s-high-selectivity-and-promising-clinical-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ELVN","LENZ","BK4139"],"gpt_icon":0},{"id":"2491597754","title":"Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2491597754","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491597754?lang=en_us&edition=full_marsco","pubTime":"2024-12-14 21:57","pubTimestamp":1734184652,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/enliven-therapeutics-nasdaqelvn-is-in-a-good-position-to-del","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":[".IXIC","TQQQ","TSYW.SI","LU2210149790.SGD","BK4588","BK4112","BK4585","MNQmain","LU2210150020.SGD","LU2095319765.USD","PSQ","IE00BGHQF748.EUR","IE00B64PRP62.GBP","ELVN","NVIW.SI","BK4007","QLD","SQQQ","IE00BKPKM429.USD","NDAQ","NQmain","LENZ","USJW.SI","BK4139","USAW.SI","IE00B3QW5Z07.USD","QID"],"gpt_icon":1},{"id":"2491329742","title":"Enliven Therapeutics Inc : Btig Initiates Coverage With Buy Rating; Price Target $42","url":"https://stock-news.laohu8.com/highlight/detail?id=2491329742","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491329742?lang=en_us&edition=full_marsco","pubTime":"2024-12-13 20:12","pubTimestamp":1734091927,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nFWN3NE0R1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2490904793","title":"Enliven Therapeutics’ ELVN-001: Navigating Competitive Challenges and Opportunities in the CML Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2490904793","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490904793?lang=en_us&edition=full_marsco","pubTime":"2024-12-11 02:55","pubTimestamp":1733856909,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Soumit Roy has maintained their bullish stance on ELVN stock, giving a Buy rating yesterday. Soumit Roy’s rating is based on t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/enliven-therapeutics-elvn-001-navigating-competitive-challenges-and-opportunities-in-the-cml-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/enliven-therapeutics-elvn-001-navigating-competitive-challenges-and-opportunities-in-the-cml-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","ELVN","LENZ"],"gpt_icon":0},{"id":"2490872928","title":"Promising Market Potential for Enliven Therapeutics’ ELVN-001 in Post-Asciminib CML Treatment Landscape","url":"https://stock-news.laohu8.com/highlight/detail?id=2490872928","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490872928?lang=en_us&edition=full_marsco","pubTime":"2024-12-09 20:35","pubTimestamp":1733747717,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Enliven Therapeutics (ELVN – Research Report) today and set a price target of $38.00...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-market-potential-for-enliven-therapeutics-elvn-001-in-post-asciminib-cml-treatment-landscape?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-market-potential-for-enliven-therapeutics-elvn-001-in-post-asciminib-cml-treatment-landscape?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","BK4212","POST","LENZ","ELVN"],"gpt_icon":0},{"id":"2483219793","title":"Enliven price target raised to $40 from $32 at Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2483219793","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483219793?lang=en_us&edition=full_marsco","pubTime":"2024-11-15 19:36","pubTimestamp":1731670575,"startTime":"0","endTime":"0","summary":"Baird raised the firm’s price target on Enliven (ELVN) to $40 from $32 and keeps an Outperform rating on the shares. The firm said they reported 3Q...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enliven-price-target-raised-to-40-from-32-at-baird?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enliven-price-target-raised-to-40-from-32-at-baird?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2483012858","title":"Enliven Therapeutics Inc : Jefferies Raises Target Price to $33 From $32","url":"https://stock-news.laohu8.com/highlight/detail?id=2483012858","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483012858?lang=en_us&edition=full_marsco","pubTime":"2024-11-14 22:40","pubTimestamp":1731595230,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3ML1E3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2483863470","title":"Enliven Therapeutics Inc:  Current Cash, Cash Equivalents and Marketable Securities Expected to Provide Cash Runway Into Late 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2483863470","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483863470?lang=en_us&edition=full_marsco","pubTime":"2024-11-14 05:05","pubTimestamp":1731531903,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA3WM78P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2483868555","title":"Enliven Therapeutics Q3 Operating Expenses USD 27.068 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2483868555","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483868555?lang=en_us&edition=full_marsco","pubTime":"2024-11-14 05:05","pubTimestamp":1731531903,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nPLXC1E02F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2483868417","title":"Press Release: Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483868417","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483868417?lang=en_us&edition=full_marsco","pubTime":"2024-11-14 05:05","pubTimestamp":1731531900,"startTime":"0","endTime":"0","summary":"Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44%  by 24 weeks and showing that ELVN-001 remains well-tolerated with no dose reductions. Continued to progress ELVN-002 with a focus on recently initiated combination clinical trials evaluating patients with HER2+ MBC and CRC. Strong balance sheet with $292 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2026. BOULDER, Colo., Nov. 13, 2024 /PRNewswire/ -- Enliven Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the third quarter ended September 30, 2024, and provided a business update, including highlights of pipeline progress.24 weeks with stable or deepening responses between weeks 12 and. -- These data continued to compare favorably to precedent Phase 1","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","LENZ","BK4232","BK4022","MBC","BK4213","CRC","BK4007","LU0456854461.SGD","LU0266512127.USD","TRAE","BK4086","BK4139","R"],"gpt_icon":0},{"id":"2481616066","title":"Enliven Therapeutics to Present at the Jefferies London Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2481616066","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481616066?lang=en_us&edition=full_marsco","pubTime":"2024-11-08 05:05","pubTimestamp":1731013500,"startTime":"0","endTime":"0","summary":"BOULDER, Colo., Nov. 7, 2024 /PRNewswire/ -- Enliven Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 9:30 a.m. GMT.About EnlivenEnliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people with cancer not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/DUhHKWf0PPol5RE3vgPfHw--~B/aD0yMTI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/2e7f6b358a50df24fca5fe3706ef10f9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/DUhHKWf0PPol5RE3vgPfHw--~B/aD0yMTI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/2e7f6b358a50df24fca5fe3706ef10f9"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/enliven-therapeutics-present-jefferies-london-210500152.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enliven-therapeutics-present-jefferies-london-210500152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4007","LENZ","ELVN","BK4137","HCSG"],"gpt_icon":0},{"id":"2479467081","title":"JonesTrading Initiates Enliven Therapeutics at Buy With $36 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2479467081","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479467081?lang=en_us&edition=full_marsco","pubTime":"2024-10-31 20:50","pubTimestamp":1730379043,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics (ELVN) has average rating of buy and price targets ranging from $32 to $39, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity and economic research","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","ELVN"],"gpt_icon":0},{"id":"2479768123","title":"Enliven initiated with a Buy at JonesResearch","url":"https://stock-news.laohu8.com/highlight/detail?id=2479768123","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479768123?lang=en_us&edition=full_marsco","pubTime":"2024-10-31 04:30","pubTimestamp":1730320225,"startTime":"0","endTime":"0","summary":"JonesResearch initiated coverage of Enliven (ELVN) with a Buy rating and $36 price target Enliven’ has “highly selective and potentially best-in-cl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enliven-initiated-with-a-buy-at-jonesresearch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enliven-initiated-with-a-buy-at-jonesresearch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2471380599","title":"TD Cowen Sticks to Their Buy Rating for Enliven Therapeutics (ELVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2471380599","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471380599?lang=en_us&edition=full_marsco","pubTime":"2024-09-30 19:15","pubTimestamp":1727694921,"startTime":"0","endTime":"0","summary":"In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Enliven Therapeutics (ELVN – Research Report). The company’s share...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-their-buy-rating-for-enliven-therapeutics-elvn-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-their-buy-rating-for-enliven-therapeutics-elvn-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELVN","LENZ","COWN","TD"],"gpt_icon":0},{"id":"2471828112","title":"Analysts Offer Insights on Healthcare Companies: Demant (OtherWILLF) and Enliven Therapeutics (ELVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2471828112","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471828112?lang=en_us&edition=full_marsco","pubTime":"2024-09-30 13:50","pubTimestamp":1727675448,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Demant (WILLF – Research Report) and Enliven Therapeutics (ELVN –...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-demant-otherwillf-and-enliven-therapeutics-elvn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-demant-otherwillf-and-enliven-therapeutics-elvn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","HCSG","ELVN","BK4137","BK4007","LENZ"],"gpt_icon":0},{"id":"2470047570","title":"BRIEF-Enliven Therapeutics Announces Positive Data Update From Phase 1 Clinical Trial Of ELVN-001 In Chronic Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2470047570","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470047570?lang=en_us&edition=full_marsco","pubTime":"2024-09-28 21:36","pubTimestamp":1727530578,"startTime":"0","endTime":"0","summary":"Sept 28  - Enliven Therapeutics Inc   :   * ENLIVEN THERAPEUTICS ANNOUNCES POSITIVE DATA UPDATE FROM PHASE 1 CLINICAL TRIAL OF ELVN-001 IN CHRONIC MYELOID LEUKEMIA   * ENLIVEN THERAPEUTICS INC - ELVN-001 WELL-TOLERATED WITH NO DOSE REDUCTIONS IN 39 PATIENTSSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","ELVN","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.imaratx.com","stockEarnings":[{"period":"1week","weight":0.0513},{"period":"1month","weight":-0.022},{"period":"3month","weight":-0.079},{"period":"6month","weight":-0.1161},{"period":"1year","weight":0.1991},{"period":"ytd","weight":-0.0524}],"compareEarnings":[{"period":"1week","weight":0.0257},{"period":"1month","weight":-0.0408},{"period":"3month","weight":-0.043},{"period":"6month","weight":0.0055},{"period":"1year","weight":0.1071},{"period":"ytd","weight":-0.0181}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.111243},{"month":2,"riseRate":0.6,"avgChangeRate":0.039232},{"month":3,"riseRate":0.8,"avgChangeRate":0.009778},{"month":4,"riseRate":0.2,"avgChangeRate":-0.092144},{"month":5,"riseRate":0.4,"avgChangeRate":0.211627},{"month":6,"riseRate":0.8,"avgChangeRate":0.014138},{"month":7,"riseRate":0.2,"avgChangeRate":-0.114241},{"month":8,"riseRate":0.4,"avgChangeRate":-0.059516},{"month":9,"riseRate":0.4,"avgChangeRate":0.140198},{"month":10,"riseRate":0.4,"avgChangeRate":0.120896},{"month":11,"riseRate":0.2,"avgChangeRate":0.059217},{"month":12,"riseRate":0.2,"avgChangeRate":-0.071568}],"exchange":"NASDAQ","name":"Enliven Treateutics","nameEN":"Enliven Treateutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Enliven Treateutics(ELVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Enliven Treateutics(ELVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Enliven Treateutics,ELVN,Enliven Treateutics股票,Enliven Treateutics股票老虎,Enliven Treateutics股票老虎国际,Enliven Treateutics行情,Enliven Treateutics股票行情,Enliven Treateutics股价,Enliven Treateutics股市,Enliven Treateutics股票价格,Enliven Treateutics股票交易,Enliven Treateutics股票购买,Enliven Treateutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Enliven Treateutics(ELVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Enliven Treateutics(ELVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}